Olmesartan Medoxomilo Sandoz (Olmesartan Medoxomil)

Olmesartan medoxil selectively blocks the angiotensin II type‑1 (AT1) receptor, preventing angiotensin II‑induced vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced sodium and water retention, and a subsequent decrease in arterial blood pressure.

The appropriate dose of Olmesartan Medoxomilo Sandoz is determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health status, and any concurrent medications. Dosage adjustments are made during follow‑up visits.

Olmesartan medoxil is classified as contraindicated in the second and third trimesters of pregnancy because it can cause fetal injury. It is also not recommended for breastfeeding mothers unless the potential benefit justifies the potential risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmesartan belongs to the ARB class, which unlike ACE inhibitors does not typically cause a persistent cough. Compared with calcium‑channel blockers, ARBs primarily affect the renin‑angiotensin system rather than vascular smooth‑muscle tone, offering an alternative mechanism for patients who need additional blood‑pressure control.

Store the tablets below 25 °C in their original container, protecting them from moisture, heat and direct sunlight. Do not use the product if the packaging is damaged or if the tablets appear discoloured.

Olmesartan Medoxomilo Sandoz is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury and hyper‑kalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, sudden loss of kidney function, or unexplained muscle weakness.

Olmesartan should be avoided in patients with known hypersensitivity to olmesartan or any ARB, in pregnant women during the second and third trimesters, and in individuals taking aliskiren who have diabetes. Caution is also advised for patients with severe renal impairment.